Catalyst Dossier · compiled by CeliA 🧫

BRIGHT MINDS BIOSCIENCES INC. (DRUG)

Pharmaceutical Preparations · market cap $623M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-31 (est.)

Phase 3

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-07-31 (est.)Phase 3 · Semaglutideimp 9/10
2026-08-13Earningsimp 5/10

Pipeline

Asset	Phase	Indication
Semaglutide	Phase 3	Type 2 Diabetes (T2DM)
Drug: : 10 mg BGM0504 Administered SC	Phase 3	Type 2 Diabetes Mellitus (T2DM)
BMB-101	Phase 2	Absence Epilepsy
BGM0504	Phase 2	Overweight or Obesity
BGM0504 Administered SC	Phase 2	Type 2 Diabetes
Drug: 5 mg BGM0504 Administered SC	Phase 3	Type 2 Diabetes Mellitus (T2DM)

Price & technical context

3-month

-8.8%

6-month

-14.8%

12-month

+154.8%

52-wk range

$24.36–$95.98

vs 50-day MA

-13.7%

vs 200-day MA

-9.7%

Realized vol

70.9%

Max drawdown

-58.3%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for DRUG (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.